Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Migraine Disorders | 77 | 2022 | 1620 | 9.390 |
Why?
|
Headache | 29 | 2020 | 1226 | 4.930 |
Why?
|
Tryptamines | 15 | 2018 | 88 | 3.180 |
Why?
|
Serotonin Receptor Agonists | 15 | 2017 | 152 | 3.070 |
Why?
|
Editorial Policies | 7 | 2016 | 451 | 2.320 |
Why?
|
Headache Disorders | 7 | 2020 | 130 | 2.070 |
Why?
|
Analgesics | 14 | 2013 | 1040 | 2.050 |
Why?
|
Cluster Headache | 8 | 2017 | 54 | 1.990 |
Why?
|
Periodicals as Topic | 9 | 2020 | 1432 | 1.590 |
Why?
|
Clinical Trials as Topic | 14 | 2018 | 7913 | 1.540 |
Why?
|
Sumatriptan | 5 | 2018 | 65 | 1.420 |
Why?
|
Awards and Prizes | 3 | 2023 | 375 | 1.360 |
Why?
|
Headache Disorders, Secondary | 2 | 2019 | 36 | 1.280 |
Why?
|
Cost of Illness | 4 | 2020 | 1859 | 1.250 |
Why?
|
Publishing | 10 | 2022 | 833 | 1.140 |
Why?
|
State Medicine | 2 | 2017 | 217 | 1.040 |
Why?
|
Vasoconstrictor Agents | 3 | 2018 | 642 | 0.950 |
Why?
|
Information Dissemination | 5 | 2021 | 1099 | 0.890 |
Why?
|
General Practice | 2 | 2017 | 100 | 0.870 |
Why?
|
Barbiturates | 4 | 2015 | 114 | 0.860 |
Why?
|
Research Report | 2 | 2015 | 355 | 0.840 |
Why?
|
Calcitonin Gene-Related Peptide | 3 | 2019 | 306 | 0.830 |
Why?
|
Nonprescription Drugs | 2 | 2013 | 116 | 0.810 |
Why?
|
Publications | 1 | 2024 | 195 | 0.790 |
Why?
|
Migraine with Aura | 3 | 2010 | 203 | 0.790 |
Why?
|
Antibodies, Monoclonal | 4 | 2019 | 9274 | 0.790 |
Why?
|
Neurology | 3 | 2020 | 763 | 0.790 |
Why?
|
Placebo Effect | 3 | 2020 | 502 | 0.780 |
Why?
|
Access to Information | 2 | 2014 | 320 | 0.750 |
Why?
|
Mind-Body Therapies | 2 | 2014 | 247 | 0.730 |
Why?
|
Pain Measurement | 5 | 2013 | 3420 | 0.720 |
Why?
|
Menstruation | 4 | 2006 | 302 | 0.710 |
Why?
|
Oxazolidinones | 3 | 2005 | 96 | 0.710 |
Why?
|
Authorship | 2 | 2020 | 271 | 0.710 |
Why?
|
Tension-Type Headache | 4 | 2010 | 77 | 0.690 |
Why?
|
Serotonin Syndrome | 1 | 2018 | 18 | 0.650 |
Why?
|
Qualitative Research | 2 | 2016 | 2682 | 0.590 |
Why?
|
Humans | 149 | 2024 | 744343 | 0.580 |
Why?
|
Personnel Management | 1 | 2016 | 55 | 0.570 |
Why?
|
Adverse Drug Reaction Reporting Systems | 3 | 2018 | 469 | 0.550 |
Why?
|
Contraceptives, Oral, Combined | 3 | 2005 | 113 | 0.550 |
Why?
|
Drug Industry | 3 | 2015 | 746 | 0.540 |
Why?
|
Peer Review, Research | 2 | 2020 | 329 | 0.540 |
Why?
|
Drug and Narcotic Control | 1 | 2016 | 146 | 0.530 |
Why?
|
Conflict of Interest | 2 | 2015 | 544 | 0.510 |
Why?
|
Evidence-Based Medicine | 9 | 2021 | 3610 | 0.500 |
Why?
|
Health Services Misuse | 2 | 2015 | 243 | 0.500 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2017 | 336 | 0.500 |
Why?
|
Publication Bias | 1 | 2015 | 162 | 0.490 |
Why?
|
Ketoprofen | 1 | 2013 | 8 | 0.480 |
Why?
|
Tromethamine | 1 | 2013 | 31 | 0.480 |
Why?
|
Piperidines | 2 | 2018 | 1602 | 0.480 |
Why?
|
Minority Health | 1 | 2015 | 87 | 0.480 |
Why?
|
Menstrual Cycle | 3 | 2007 | 551 | 0.470 |
Why?
|
Oseltamivir | 1 | 2014 | 75 | 0.470 |
Why?
|
Carbazoles | 2 | 2013 | 226 | 0.470 |
Why?
|
Primary Health Care | 8 | 2020 | 4558 | 0.470 |
Why?
|
Health Surveys | 3 | 2020 | 4037 | 0.460 |
Why?
|
Statistics as Topic | 3 | 2021 | 2373 | 0.450 |
Why?
|
Contraceptives, Oral, Hormonal | 3 | 2017 | 188 | 0.440 |
Why?
|
Government Regulation | 2 | 2017 | 522 | 0.440 |
Why?
|
Drug Tolerance | 2 | 2011 | 376 | 0.440 |
Why?
|
Health Services | 1 | 2018 | 758 | 0.440 |
Why?
|
Guidelines as Topic | 4 | 2021 | 1405 | 0.430 |
Why?
|
Wit and Humor as Topic | 1 | 2012 | 31 | 0.430 |
Why?
|
PubMed | 1 | 2013 | 123 | 0.430 |
Why?
|
Inappropriate Prescribing | 1 | 2015 | 202 | 0.430 |
Why?
|
Biomedical Research | 6 | 2020 | 3309 | 0.420 |
Why?
|
Patient Satisfaction | 5 | 2021 | 3396 | 0.420 |
Why?
|
Diagnostic Errors | 3 | 2017 | 1257 | 0.420 |
Why?
|
Pyrroles | 1 | 2018 | 1146 | 0.410 |
Why?
|
Research Design | 5 | 2021 | 5987 | 0.410 |
Why?
|
Disclosure | 2 | 2015 | 736 | 0.410 |
Why?
|
Fructose | 4 | 2007 | 288 | 0.400 |
Why?
|
Meditation | 1 | 2014 | 242 | 0.390 |
Why?
|
Functional Laterality | 1 | 2018 | 2290 | 0.390 |
Why?
|
Musculoskeletal Manipulations | 1 | 2010 | 25 | 0.380 |
Why?
|
Primary Prevention | 1 | 2018 | 1167 | 0.380 |
Why?
|
Prevalence | 12 | 2020 | 15226 | 0.370 |
Why?
|
Benzopyrans | 1 | 2010 | 64 | 0.360 |
Why?
|
Behavior Therapy | 3 | 2012 | 865 | 0.360 |
Why?
|
Hematologic Tests | 1 | 2011 | 240 | 0.350 |
Why?
|
Antidepressive Agents | 2 | 2018 | 2838 | 0.340 |
Why?
|
Health Status Disparities | 1 | 2020 | 1797 | 0.330 |
Why?
|
Estrogens | 5 | 2007 | 1566 | 0.330 |
Why?
|
Interprofessional Relations | 1 | 2015 | 1011 | 0.330 |
Why?
|
Anticonvulsants | 3 | 2018 | 1916 | 0.330 |
Why?
|
Urinalysis | 1 | 2011 | 369 | 0.320 |
Why?
|
Physician's Role | 2 | 2013 | 943 | 0.320 |
Why?
|
Female | 63 | 2022 | 380194 | 0.310 |
Why?
|
Societies, Medical | 3 | 2020 | 3743 | 0.310 |
Why?
|
Population Surveillance | 3 | 2017 | 2616 | 0.310 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2015 | 9959 | 0.300 |
Why?
|
Choice Behavior | 1 | 2013 | 803 | 0.300 |
Why?
|
Vascular Diseases | 2 | 2013 | 1161 | 0.300 |
Why?
|
Data Interpretation, Statistical | 1 | 2017 | 2716 | 0.300 |
Why?
|
Health Care Reform | 1 | 2016 | 1261 | 0.290 |
Why?
|
Pyridines | 1 | 2018 | 2825 | 0.290 |
Why?
|
United States | 23 | 2020 | 69872 | 0.280 |
Why?
|
Butorphanol | 1 | 2006 | 12 | 0.280 |
Why?
|
Pregnancy Complications | 3 | 2007 | 2861 | 0.280 |
Why?
|
Practice Guidelines as Topic | 8 | 2021 | 7279 | 0.280 |
Why?
|
Patient Selection | 1 | 2018 | 4215 | 0.270 |
Why?
|
Drug Approval | 2 | 2018 | 742 | 0.270 |
Why?
|
Nutrition Surveys | 1 | 2013 | 1660 | 0.270 |
Why?
|
Mendelian Randomization Analysis | 2 | 2021 | 967 | 0.270 |
Why?
|
Fellowships and Scholarships | 1 | 2014 | 1076 | 0.270 |
Why?
|
Insurance Coverage | 1 | 2017 | 1901 | 0.270 |
Why?
|
Registries | 4 | 2017 | 8089 | 0.270 |
Why?
|
Academic Medical Centers | 2 | 2016 | 2759 | 0.260 |
Why?
|
Stiff-Person Syndrome | 1 | 2005 | 28 | 0.260 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 1364 | 0.250 |
Why?
|
Benzamides | 1 | 2010 | 1379 | 0.240 |
Why?
|
Analgesics, Non-Narcotic | 2 | 2018 | 365 | 0.240 |
Why?
|
Patient Participation | 1 | 2013 | 1457 | 0.240 |
Why?
|
Dysmenorrhea | 1 | 2005 | 86 | 0.240 |
Why?
|
Postpartum Period | 1 | 2010 | 1086 | 0.240 |
Why?
|
Cyclohexanols | 1 | 2004 | 127 | 0.240 |
Why?
|
Workplace | 2 | 2020 | 836 | 0.240 |
Why?
|
Botulinum Toxins, Type A | 3 | 2018 | 213 | 0.230 |
Why?
|
Vascular Headaches | 1 | 2002 | 22 | 0.220 |
Why?
|
Phenobarbital | 1 | 2003 | 193 | 0.220 |
Why?
|
Medicine | 2 | 2020 | 946 | 0.220 |
Why?
|
Heart Septal Defects, Atrial | 1 | 2006 | 478 | 0.220 |
Why?
|
Influenza, Human | 1 | 2014 | 1479 | 0.220 |
Why?
|
Triazoles | 3 | 2007 | 911 | 0.210 |
Why?
|
Analgesics, Opioid | 3 | 2015 | 3674 | 0.210 |
Why?
|
Adult | 40 | 2021 | 214055 | 0.210 |
Why?
|
Hospitals, Special | 1 | 2003 | 101 | 0.210 |
Why?
|
Needs Assessment | 3 | 2016 | 1147 | 0.210 |
Why?
|
Male | 41 | 2021 | 350118 | 0.210 |
Why?
|
Antiviral Agents | 1 | 2014 | 2987 | 0.200 |
Why?
|
Economics, Medical | 1 | 2022 | 113 | 0.200 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2006 | 430 | 0.200 |
Why?
|
Double-Blind Method | 11 | 2021 | 12026 | 0.200 |
Why?
|
Rehabilitation Centers | 1 | 2003 | 254 | 0.190 |
Why?
|
Terminology as Topic | 4 | 2021 | 1547 | 0.190 |
Why?
|
Drug Labeling | 2 | 2018 | 233 | 0.190 |
Why?
|
Botulinum Toxins | 1 | 2002 | 191 | 0.190 |
Why?
|
Checklist | 2 | 2021 | 833 | 0.190 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2018 | 4266 | 0.190 |
Why?
|
Personnel, Hospital | 1 | 2003 | 283 | 0.190 |
Why?
|
Health Care Surveys | 2 | 2020 | 2453 | 0.190 |
Why?
|
Treatment Outcome | 19 | 2021 | 63114 | 0.190 |
Why?
|
Drug Combinations | 2 | 2005 | 1959 | 0.180 |
Why?
|
Politics | 2 | 2017 | 791 | 0.180 |
Why?
|
Preventive Medicine | 1 | 2002 | 264 | 0.180 |
Why?
|
Education, Medical | 2 | 2017 | 1721 | 0.170 |
Why?
|
Quality Control | 3 | 2021 | 841 | 0.170 |
Why?
|
Absenteeism | 1 | 2020 | 250 | 0.170 |
Why?
|
Telephone | 1 | 2002 | 617 | 0.170 |
Why?
|
Physicians, Primary Care | 2 | 2016 | 591 | 0.170 |
Why?
|
Iontophoresis | 1 | 2018 | 74 | 0.170 |
Why?
|
Epidemiology | 1 | 2021 | 287 | 0.170 |
Why?
|
Menopause | 1 | 2007 | 1626 | 0.170 |
Why?
|
Transdermal Patch | 1 | 2018 | 51 | 0.160 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2003 | 632 | 0.160 |
Why?
|
Patients | 1 | 2005 | 900 | 0.160 |
Why?
|
Review Literature as Topic | 2 | 2014 | 336 | 0.160 |
Why?
|
Epidemiologic Research Design | 1 | 2021 | 367 | 0.160 |
Why?
|
Costs and Cost Analysis | 2 | 2022 | 1681 | 0.150 |
Why?
|
Attitude of Health Personnel | 2 | 2020 | 3843 | 0.150 |
Why?
|
Drug Prescriptions | 2 | 2004 | 1637 | 0.150 |
Why?
|
Specialization | 1 | 2002 | 777 | 0.150 |
Why?
|
Efficiency | 1 | 2020 | 462 | 0.150 |
Why?
|
Stroke | 4 | 2017 | 9981 | 0.150 |
Why?
|
Databases, Bibliographic | 2 | 2015 | 128 | 0.150 |
Why?
|
Indoles | 2 | 2005 | 1839 | 0.150 |
Why?
|
Denmark | 1 | 2019 | 738 | 0.150 |
Why?
|
Delphi Technique | 2 | 2017 | 778 | 0.150 |
Why?
|
Burns, Chemical | 1 | 2018 | 159 | 0.150 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2019 | 11725 | 0.150 |
Why?
|
Formularies as Topic | 1 | 2017 | 91 | 0.150 |
Why?
|
Biological Evolution | 1 | 2002 | 1076 | 0.140 |
Why?
|
Marketing | 1 | 2018 | 212 | 0.140 |
Why?
|
Amitriptyline | 1 | 2016 | 110 | 0.140 |
Why?
|
Workload | 1 | 2002 | 850 | 0.140 |
Why?
|
Professional Competence | 1 | 2020 | 447 | 0.140 |
Why?
|
Middle Aged | 26 | 2021 | 213383 | 0.140 |
Why?
|
Electronic Health Records | 3 | 2018 | 4468 | 0.140 |
Why?
|
Pregnancy | 5 | 2013 | 29144 | 0.140 |
Why?
|
Patient Education as Topic | 2 | 2021 | 2278 | 0.130 |
Why?
|
Prescriptions | 1 | 2018 | 387 | 0.130 |
Why?
|
England | 1 | 2016 | 522 | 0.130 |
Why?
|
Brain Ischemia | 1 | 2009 | 3265 | 0.130 |
Why?
|
Hypnotics and Sedatives | 1 | 2003 | 1162 | 0.130 |
Why?
|
Federal Government | 1 | 2017 | 260 | 0.130 |
Why?
|
Professional-Patient Relations | 1 | 2020 | 737 | 0.130 |
Why?
|
New York | 1 | 2017 | 886 | 0.120 |
Why?
|
Clinical Protocols | 2 | 2015 | 1462 | 0.120 |
Why?
|
European Union | 1 | 2015 | 158 | 0.120 |
Why?
|
Sensation Disorders | 1 | 2015 | 155 | 0.120 |
Why?
|
Facial Nerve Diseases | 1 | 2014 | 50 | 0.120 |
Why?
|
Science | 1 | 2017 | 241 | 0.120 |
Why?
|
Spinal Nerves | 1 | 2014 | 86 | 0.120 |
Why?
|
Aphasia | 1 | 2015 | 179 | 0.120 |
Why?
|
Mental Disorders | 3 | 2017 | 6600 | 0.120 |
Why?
|
Censuses | 1 | 2014 | 200 | 0.110 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2016 | 3923 | 0.110 |
Why?
|
Random Allocation | 1 | 2018 | 2429 | 0.110 |
Why?
|
Multicenter Studies as Topic | 1 | 2018 | 1677 | 0.110 |
Why?
|
Diagnosis, Differential | 4 | 2015 | 12959 | 0.110 |
Why?
|
Substance-Related Disorders | 1 | 2010 | 4258 | 0.110 |
Why?
|
Early Termination of Clinical Trials | 1 | 2013 | 68 | 0.110 |
Why?
|
Natural Science Disciplines | 1 | 2012 | 3 | 0.110 |
Why?
|
Tablets | 2 | 2005 | 145 | 0.110 |
Why?
|
Cicatrix | 1 | 2018 | 764 | 0.110 |
Why?
|
Administration, Oral | 3 | 2005 | 3913 | 0.110 |
Why?
|
Pain | 2 | 2005 | 4986 | 0.110 |
Why?
|
Cost-Benefit Analysis | 2 | 2022 | 5391 | 0.110 |
Why?
|
Academies and Institutes | 1 | 2014 | 317 | 0.110 |
Why?
|
Economics | 1 | 2013 | 146 | 0.100 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2008 | 1240 | 0.100 |
Why?
|
History, 21st Century | 2 | 2008 | 1534 | 0.100 |
Why?
|
Ethics, Medical | 1 | 2017 | 792 | 0.100 |
Why?
|
Pandemics | 2 | 2023 | 8388 | 0.100 |
Why?
|
Adolescent | 12 | 2020 | 85781 | 0.100 |
Why?
|
Pain Clinics | 2 | 2016 | 49 | 0.100 |
Why?
|
Cerebrospinal Fluid Pressure | 1 | 2010 | 35 | 0.100 |
Why?
|
MELAS Syndrome | 1 | 2011 | 50 | 0.090 |
Why?
|
Risk Factors | 11 | 2012 | 72290 | 0.090 |
Why?
|
Education, Medical, Continuing | 1 | 2016 | 840 | 0.090 |
Why?
|
Neuroprotective Agents | 2 | 2007 | 941 | 0.090 |
Why?
|
CADASIL | 1 | 2011 | 84 | 0.090 |
Why?
|
History, 20th Century | 2 | 2008 | 2740 | 0.090 |
Why?
|
Sexual Behavior | 1 | 2019 | 2057 | 0.090 |
Why?
|
Quality of Health Care | 1 | 2005 | 4371 | 0.090 |
Why?
|
Ischemic Attack, Transient | 1 | 2015 | 935 | 0.090 |
Why?
|
Demography | 1 | 2014 | 1656 | 0.090 |
Why?
|
Women's Health | 1 | 1999 | 2034 | 0.090 |
Why?
|
Intracranial Thrombosis | 1 | 2010 | 113 | 0.090 |
Why?
|
Placebos | 4 | 2007 | 1676 | 0.090 |
Why?
|
Patient Admission | 1 | 2017 | 1380 | 0.080 |
Why?
|
Pilot Projects | 3 | 2021 | 8324 | 0.080 |
Why?
|
Sex Factors | 2 | 2020 | 10397 | 0.080 |
Why?
|
Health Promotion | 1 | 2020 | 2205 | 0.080 |
Why?
|
Young Adult | 5 | 2020 | 56430 | 0.080 |
Why?
|
Coronary Disease | 1 | 2003 | 6077 | 0.080 |
Why?
|
Neoplasms | 1 | 2017 | 21683 | 0.080 |
Why?
|
Cohort Studies | 4 | 2019 | 40561 | 0.080 |
Why?
|
Serotonin Antagonists | 1 | 2008 | 144 | 0.080 |
Why?
|
Nerve Block | 1 | 2014 | 644 | 0.080 |
Why?
|
Vasoconstriction | 1 | 2010 | 597 | 0.080 |
Why?
|
Activities of Daily Living | 2 | 2007 | 2418 | 0.080 |
Why?
|
Biofeedback, Psychology | 1 | 2008 | 115 | 0.080 |
Why?
|
Sex Characteristics | 2 | 2013 | 2585 | 0.070 |
Why?
|
Fever | 1 | 2015 | 1616 | 0.070 |
Why?
|
Phytoestrogens | 1 | 2007 | 61 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3218 | 0.070 |
Why?
|
Giant Cell Arteritis | 1 | 2011 | 292 | 0.070 |
Why?
|
Sickness Impact Profile | 1 | 2007 | 302 | 0.070 |
Why?
|
Acute Disease | 3 | 2007 | 7149 | 0.070 |
Why?
|
Brain Diseases | 1 | 2015 | 1563 | 0.070 |
Why?
|
Menstruation Disturbances | 1 | 2007 | 148 | 0.070 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2008 | 434 | 0.070 |
Why?
|
Information Storage and Retrieval | 1 | 2012 | 824 | 0.070 |
Why?
|
Meta-Analysis as Topic | 2 | 2021 | 1344 | 0.070 |
Why?
|
Progesterone Congeners | 1 | 2005 | 42 | 0.070 |
Why?
|
Program Evaluation | 1 | 2014 | 2488 | 0.070 |
Why?
|
Neuromuscular Agents | 1 | 2007 | 134 | 0.070 |
Why?
|
Longitudinal Studies | 3 | 2018 | 13989 | 0.070 |
Why?
|
Severity of Illness Index | 3 | 2013 | 15540 | 0.070 |
Why?
|
Polymorphism, Genetic | 2 | 2006 | 4328 | 0.070 |
Why?
|
Sex Distribution | 2 | 2002 | 2297 | 0.070 |
Why?
|
Ergotamine | 1 | 2005 | 7 | 0.070 |
Why?
|
Retreatment | 1 | 2007 | 610 | 0.060 |
Why?
|
Ethinyl Estradiol | 1 | 2005 | 116 | 0.060 |
Why?
|
Malaria | 1 | 2015 | 1239 | 0.060 |
Why?
|
Lithium | 1 | 2008 | 601 | 0.060 |
Why?
|
Secondary Prevention | 1 | 2011 | 1530 | 0.060 |
Why?
|
Calcium Channel Blockers | 1 | 2008 | 690 | 0.060 |
Why?
|
Therapeutic Equivalency | 1 | 2005 | 141 | 0.060 |
Why?
|
Serotonin 5-HT1 Receptor Agonists | 1 | 2004 | 43 | 0.060 |
Why?
|
Administration, Intranasal | 1 | 2006 | 446 | 0.060 |
Why?
|
Comorbidity | 2 | 2017 | 10388 | 0.060 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 2282 | 0.060 |
Why?
|
Life Style | 2 | 2008 | 3835 | 0.060 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2007 | 367 | 0.060 |
Why?
|
Methylamines | 1 | 2005 | 123 | 0.060 |
Why?
|
Jurisprudence | 1 | 2004 | 110 | 0.060 |
Why?
|
Research | 1 | 2012 | 1999 | 0.060 |
Why?
|
Pyrrolidines | 1 | 2005 | 342 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2016 | 10943 | 0.060 |
Why?
|
Pharmaceutical Preparations | 1 | 2011 | 1071 | 0.060 |
Why?
|
Whiplash Injuries | 1 | 2002 | 15 | 0.060 |
Why?
|
Child | 7 | 2020 | 77709 | 0.050 |
Why?
|
Progestins | 1 | 2005 | 306 | 0.050 |
Why?
|
Age Distribution | 2 | 2015 | 2902 | 0.050 |
Why?
|
Chronic Disease | 2 | 2010 | 9146 | 0.050 |
Why?
|
Retrospective Studies | 4 | 2020 | 77449 | 0.050 |
Why?
|
Ovary | 1 | 2007 | 981 | 0.050 |
Why?
|
Defense Mechanisms | 1 | 2002 | 178 | 0.050 |
Why?
|
Insurance, Health | 1 | 2014 | 2494 | 0.050 |
Why?
|
Contract Services | 1 | 2002 | 94 | 0.050 |
Why?
|
Quality Indicators, Health Care | 1 | 2012 | 1831 | 0.050 |
Why?
|
Drug Therapy | 1 | 2005 | 497 | 0.050 |
Why?
|
Medical History Taking | 1 | 2005 | 783 | 0.050 |
Why?
|
Curriculum | 1 | 2014 | 3605 | 0.050 |
Why?
|
Electric Stimulation Therapy | 1 | 2007 | 605 | 0.050 |
Why?
|
Referral and Consultation | 2 | 2008 | 3528 | 0.050 |
Why?
|
Pre-Eclampsia | 1 | 2010 | 1200 | 0.050 |
Why?
|
Treatment Failure | 1 | 2007 | 2618 | 0.050 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3086 | 0.050 |
Why?
|
Cross-Over Studies | 2 | 2008 | 2029 | 0.050 |
Why?
|
Multiple Sclerosis | 1 | 2015 | 3079 | 0.050 |
Why?
|
Combined Modality Therapy | 2 | 2003 | 8642 | 0.050 |
Why?
|
Aged | 8 | 2020 | 163280 | 0.050 |
Why?
|
Recurrence | 2 | 2005 | 8340 | 0.050 |
Why?
|
Evoked Potentials | 1 | 2006 | 1056 | 0.050 |
Why?
|
Smoking | 1 | 2017 | 8987 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2008 | 4933 | 0.050 |
Why?
|
Pregnancy Trimester, Third | 1 | 2003 | 571 | 0.050 |
Why?
|
Estrogen Replacement Therapy | 1 | 2007 | 1203 | 0.050 |
Why?
|
Cardiovascular Diseases | 1 | 2006 | 15165 | 0.050 |
Why?
|
Inservice Training | 1 | 2003 | 392 | 0.040 |
Why?
|
Time Factors | 5 | 2007 | 40075 | 0.040 |
Why?
|
Perception | 2 | 2020 | 1198 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2011 | 2219 | 0.040 |
Why?
|
Pregnancy Trimester, Second | 1 | 2003 | 732 | 0.040 |
Why?
|
Counseling | 1 | 2008 | 1523 | 0.040 |
Why?
|
Technology Assessment, Biomedical | 1 | 2022 | 306 | 0.040 |
Why?
|
Pain Perception | 1 | 2021 | 191 | 0.040 |
Why?
|
Patient Care Planning | 1 | 2005 | 921 | 0.040 |
Why?
|
Physical Examination | 1 | 2005 | 1237 | 0.040 |
Why?
|
Adaptation, Psychological | 1 | 2010 | 2576 | 0.040 |
Why?
|
Physicians | 2 | 2013 | 4567 | 0.040 |
Why?
|
Prospective Studies | 5 | 2020 | 53288 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 2006 | 1584 | 0.040 |
Why?
|
Research Support as Topic | 1 | 2002 | 705 | 0.040 |
Why?
|
Boston | 2 | 2016 | 9313 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2016 | 14722 | 0.040 |
Why?
|
Forecasting | 1 | 2006 | 2951 | 0.040 |
Why?
|
Environment | 1 | 2002 | 1124 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2002 | 933 | 0.030 |
Why?
|
Cerebrovascular Circulation | 1 | 2006 | 2731 | 0.030 |
Why?
|
Efficiency, Organizational | 1 | 2020 | 695 | 0.030 |
Why?
|
Emergencies | 1 | 2002 | 1170 | 0.030 |
Why?
|
Empathy | 1 | 2020 | 474 | 0.030 |
Why?
|
Neurosurgical Procedures | 1 | 2007 | 2002 | 0.030 |
Why?
|
Age of Onset | 1 | 2002 | 3271 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2014 | 7659 | 0.030 |
Why?
|
Attitude to Health | 1 | 2004 | 2052 | 0.030 |
Why?
|
Heart Rate | 1 | 2006 | 4091 | 0.030 |
Why?
|
Disease Progression | 1 | 2011 | 13284 | 0.030 |
Why?
|
Aged, 80 and over | 2 | 2018 | 57776 | 0.030 |
Why?
|
Prognosis | 2 | 2008 | 29063 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2006 | 17446 | 0.030 |
Why?
|
Disease Management | 1 | 2005 | 2459 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2016 | 981 | 0.030 |
Why?
|
Military Medicine | 1 | 2015 | 176 | 0.030 |
Why?
|
Culture | 1 | 2017 | 633 | 0.030 |
Why?
|
Health Policy | 2 | 2017 | 2661 | 0.030 |
Why?
|
Pregnancy Outcome | 1 | 2003 | 2795 | 0.030 |
Why?
|
Health Behavior | 1 | 2004 | 2636 | 0.030 |
Why?
|
Inpatients | 1 | 2003 | 2518 | 0.030 |
Why?
|
Bupivacaine | 1 | 2014 | 411 | 0.020 |
Why?
|
Animals | 3 | 2010 | 168757 | 0.020 |
Why?
|
Blood Pressure | 1 | 2006 | 8554 | 0.020 |
Why?
|
Body Mass Index | 1 | 2007 | 12720 | 0.020 |
Why?
|
Massachusetts | 1 | 2002 | 8663 | 0.020 |
Why?
|
Reference Standards | 1 | 2013 | 1025 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2002 | 3229 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2009 | 11727 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 681 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 20822 | 0.020 |
Why?
|
Quality of Life | 3 | 2020 | 12804 | 0.020 |
Why?
|
Anesthetics, Local | 1 | 2014 | 985 | 0.020 |
Why?
|
Clinical Competence | 1 | 2003 | 4687 | 0.020 |
Why?
|
Ohio | 1 | 2007 | 337 | 0.020 |
Why?
|
Communication | 1 | 2020 | 3749 | 0.020 |
Why?
|
Injections, Intramuscular | 1 | 2007 | 552 | 0.020 |
Why?
|
Risk Assessment | 1 | 2007 | 23338 | 0.020 |
Why?
|
Chemoprevention | 1 | 2007 | 319 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2020 | 4245 | 0.020 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12261 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2004 | 39050 | 0.010 |
Why?
|
Acetaminophen | 1 | 2005 | 545 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 7729 | 0.010 |
Why?
|
Caffeine | 1 | 2005 | 699 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 25043 | 0.010 |
Why?
|
ROC Curve | 1 | 2006 | 3527 | 0.010 |
Why?
|
Psychometrics | 1 | 2007 | 3002 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 19905 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 12354 | 0.010 |
Why?
|
Data Collection | 1 | 2007 | 3341 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2001 | 841 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2012 | 5319 | 0.010 |
Why?
|
Aspirin | 1 | 2005 | 3282 | 0.010 |
Why?
|
Models, Biological | 1 | 2006 | 9583 | 0.010 |
Why?
|
Incidence | 1 | 2007 | 20947 | 0.010 |
Why?
|
Depression | 1 | 2008 | 7766 | 0.000 |
Why?
|
Hypertension | 1 | 2008 | 8480 | 0.000 |
Why?
|
Obesity | 1 | 2007 | 12745 | 0.000 |
Why?
|